Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment ConferencePRNewsWire • 09/05/23
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021PRNewsWire • 08/16/23
Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business AchievementsPRNewsWire • 08/03/23
Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial OfficerPRNewsWire • 07/13/23
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023PRNewsWire • 06/03/23
Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business AchievementsPRNewsWire • 05/15/23
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023PRNewsWire • 04/26/23
Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023PRNewsWire • 04/17/23
Elevation Oncology to Present at the American Association of Cancer Research (AACR) Annual Meeting 2023PRNewsWire • 03/14/23
Elevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/09/23
Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO TransitionPRNewsWire • 01/06/23
Elevation Oncology to Participate at the JMP Securities Hematology and Oncology SummitPRNewsWire • 11/30/22
Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressPRNewsWire • 11/03/22
Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company ProgressPRNewsWire • 08/04/22